4.6 Article

Determination of 12 anti-obesity drugs in human plasma by a 96-well protein precipitation plate using HPLC-MS

Journal

RSC ADVANCES
Volume 12, Issue 40, Pages 26016-26022

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/d2ra03423a

Keywords

-

Funding

  1. Central Government guides the development of local science and technology project of Hebei Province [226Z7708G]
  2. key research and development program of Hebei Province, China [223777116D]

Ask authors/readers for more resources

An analytical method using a 96-well protein precipitation plate combined with HPLC-MS/MS was developed and validated for the simultaneous determination of 12 anti-obesity drugs in human plasma. This method offers advantages of efficient and rapid analysis, simple operation, high accuracy and sensitivity. It can be used for clinically monitoring adverse reactions and guiding the appropriate use of weight-loss drugs for obese individuals.
An analytical method was developed and validated for the simultaneous determination of 12 anti-obesity drugs (methylephedrine (MER), amphetamine (AMP), fenfluramine (FEN), bupropion (BUP), fluoxetine (FLU), sibutramine (SIBU), bisacodyl (BISA), bumetanide (BUM), lovastatin (LOVA), simvastatin (SIM), rimonabant (RIMO), and fenofibrate (FENO)) in human plasma by a 96-well protein precipitation plate combined with high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). The 96-well protein precipitation plate was chosen for simultaneous pretreatment of large sample volumes, making the whole process more efficient and faster. Drugs were separated on an Agilent Poroshell 120 EC-C18 column, and detected by MS/MS under multiple reaction monitoring (MRM) mode. The developed method was validated in terms of linearity, matrix effect, accuracy and precision. A good linearity was obtained in the range of 0.1-20.0 ng mL(-1) for fenfluramine, bupropion, fluoxetine, sibutramine, bisacodyl, and rimonabant; and 0.5-20.0 ng mL(-1) for methylephedrine, amphetamine, bumetanide, lovastatin, simvastatin, and fenofibrate with a correlation coefficient above 0.995. The method was fully validated with an acceptable accuracy of 75.63-108.21%, matrix effect of 80.41-117.71% except for fenofibrate (76.07% at low concentration levels), and precision of 0.32-13.12%. Owing to the advantages of simple operation, high accuracy and sensitivity, this method is suitable for the rapid and simultaneous detection of 12 anti-obesity drugs in human plasma, providing support for clinically monitoring the development of adverse reactions and guiding the rational and appropriate use of weight-loss drugs for obese people.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available